Overview

Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery

Status:
Not yet recruiting

Trial end date:
2025-08-21

Target enrollment:

Participant gender:

Summary

This study is a prospective, open label, multicenter, randomized controlled clinical trial. The main purpose of the study is to evaluate the efficacy and safety of nimotuzumab combined with concurrent radiotherapy versus radiotherapy alone in high-risk patients with HNSCC not suitable for cisplatin after surgery. The subjects were randomly divided into study group (nimotuzumab combined with concurrent radiotherapy) and control group (radiotherapy alone) by 1∶1 stratified random method.

Phase:

Phase 2

Details

Lead Sponsor:

Eye & ENT Hospital of Fudan University

Treatments:

Nimotuzumab